Cabosun Ii: Cabozantinib Versus Sunitinib for Metastatic Variant Histology Renal Cell Carcinoma
Latest Information Update: 26 Jun 2023
At a glance
- Drugs Cabozantinib (Primary) ; Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms Cabosun II
- 20 Jun 2023 Planned End Date changed from 31 Jul 2023 to 31 Jul 2025.
- 20 Jun 2023 Planned primary completion date changed from 31 Jul 2023 to 31 Jul 2025.
- 06 Jun 2023 Primary endpoint (Progression-Free Survival (PFS) Evaluated Using RECIST 1.1 Criteria) has not been met, according to Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.